Cerus Corporation (CERS)
NASDAQ: CERS · Real-Time Price · USD
1.240
-0.050 (-3.88%)
At close: Apr 4, 2025, 4:00 PM
1.250
+0.010 (0.81%)
After-hours: Apr 4, 2025, 6:08 PM EDT

Company Description

Cerus Corporation operates as a biomedical products company.

The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.

Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced.

It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally.

The company was incorporated in 1991 and is headquartered in Concord, California.

Cerus Corporation
Cerus logo
Country United States
Founded 1991
IPO Date Jan 30, 1997
Industry Medical Devices
Sector Healthcare
Employees 630
CEO William Greenman

Contact Details

Address:
1220 Concord Avenue, Suite 600
Concord, California 94520
United States
Phone 925 288 6000
Website cerus.com

Stock Details

Ticker Symbol CERS
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001020214
CUSIP Number 157085101
ISIN Number US1570851014
Employer ID 68-0262011
SIC Code 3841

Key Executives

Name Position
William M. Greenman President, Chief Executive Officer and Director
Kevin D. Green CPA Vice President of Finance and Chief Financial Officer
Vivek K. Jayaraman Chief Operating Officer
Chrystal Jensen J.D. Chief Legal Officer and General Counsel
Dr. Richard J. Benjamin MBChB, Ph.D. Chief Medical Officer
Dr. Laurence M. Corash M.D. Co-Founder and Chief Scientific Officer
Lainie Corten Vice President of Global Marketing
Carol M. Moore Senior Vice President of Regulatory Affairs, Quality and Clinical
Dr. Nina Mufti Ph.D. Senior Vice President of Research and Development
Jessica Hanover Ph.D. Vice President of Corporate Affairs

Latest SEC Filings

Date Type Title
Mar 4, 2025 144 Filing
Mar 3, 2025 144 Filing
Mar 3, 2025 144 Filing
Feb 26, 2025 10-K Annual Report
Feb 20, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 6, 2025 8-K Current Report
Jan 13, 2025 8-K Current Report
Jan 10, 2025 SCHEDULE 13G/A Filing
Dec 16, 2024 144 Filing